Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Kort integrativ og nevrokognitiv terapi for unge voksne med borderline personlighetsforstyrrelse (SINTYA)

10. november 2026 oppdatert av: Centre Hospitalier Universitaire de Nīmes

Kort integrativ og nevrokognitiv terapi for unge voksne med borderline personlighetsforstyrrelse: en studiemodell for impulsivitetshåndtering

Borderline personality disorder (BPD) is a severe, high-suicidal psychiatric disorder associated with impulsive, endangering behaviors. Young patients between 16 and 25 years old do not respond to traditional psychotherapies, which are often long and not adapted to their neurocognitive alterations linked to early trauma. The study authors hypothesize the SINTYA therapy program (one group session and one individual session weekly for 10 weeks) would reduce the level of impulsivity and clinical symptomatology (severity of the BPD; emotional regulation difficulties; dissociative symptoms; aggressiveness; ruminations; the number of self-destructive behaviors and suicidal acts; impulsive behaviors; level of suicide risk and hopelessness; the number of psychiatric hospitalizations and emergency visits for psychiatric reasons; and finally improving psychosocial functioning).

Studieoversikt

Status

Fullført

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

74

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

16 år til 25 år (Barn, Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Diagnosis of BPD according to DSM-5 criteria and BPQ-80 scale.
  • High BPD severity level: ZAN-BPD (score ≥ 18/36).
  • Understand, write and read French.
  • Be able to understand the nature, purpose and methodology of the study and agree to cooperate during evaluations.
  • Have signed the informed consent.
  • For minor patients, have signed the parental consent by at least one holder of parental authority.

Exclusion Criteria:

  • Refusal to participate.
  • Existence of a neurological pathology or cerebral sequelae of organic origin which could affect neurocognitive performance.
  • Intelligence quotient < 70.
  • Lifetime diagnosis of schizoaffective disorder or schizophrenia (MINI-7).
  • Previous or current participation in specific psychotherapy for BPD.
  • Subject deprived of liberty (by judicial or administrative decision) and/or protected by law.
  • Inclusion in another study including psychotherapy for the duration of the study.
  • Inclusion in a drug RIPH1 study or in a REC study (European regulation of clinical trials) for the entire duration of the study.
  • Subject in period of exclusion from another research protocol.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Ingen inngripen: Styre
Eksperimentell: SINTYA-gruppen

10-week psychotherapy program consisting of a weekly 1h30 hour group therapy session plus 1 hour individual therapy session

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Variation in explicit impulsivity between groups
Tidsramme: Baseline

UPPS-S (Impulsive Behavior Scale Short version score)

Baseline
Variation in explicit impulsivity between groups
Tidsramme: Month 4

UPPS-S (Impulsive Behavior Scale Short version score)

Month 4

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Variation in explicit impulsivity between groups
Tidsramme: Month 7

UPPS-S (Impulsive Behavior Scale Short version score)

Month 7
Variation in impulsiveness between groups
Tidsramme: Baseline

Barratt Impulsiveness Scale (BIS-11) (score out of 120)

Baseline
Variation in impulsiveness between groups
Tidsramme: Month 4

Barratt Impulsiveness Scale (BIS-11) (score out of 120)

Month 4
Variation in impulsiveness between groups
Tidsramme: Month 7

Barratt Impulsiveness Scale (BIS-11) (score out of 120)

Month 7
BPD severity level between groups
Tidsramme: Baseline

Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36)

Baseline
BPD severity level between groups
Tidsramme: Month 4

Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36)

Month 4
BPD severity level between groups
Tidsramme: Month 7

Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36)

Month 7
Emotional regulation capacities between groups
Tidsramme: Baseline

Difficulties in Emotion Regulation Scale (DERS-18)

Baseline
Emotional regulation capacities between groups
Tidsramme: Month 4

Difficulties in Emotion Regulation Scale (DERS-18)

Month 4
Emotional regulation capacities between groups
Tidsramme: Month 7

Difficulties in Emotion Regulation Scale (DERS-18)

Month 7
Dissociative symptoms between groups
Tidsramme: Baseline

Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder

Baseline
Dissociative symptoms between groups
Tidsramme: Month 4

Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder

Month 4
Dissociative symptoms between groups
Tidsramme: Month 7

Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder

Month 7
Aggression between groups
Tidsramme: Baseline

Aggression Questionnaire (AQ-12)

Baseline
Aggression between groups
Tidsramme: Month 4

Aggression Questionnaire (AQ-12)

Month 4
Aggression between groups
Tidsramme: Month 7

Aggression Questionnaire (AQ-12)

Month 7
Ruminations between groups
Tidsramme: Baseline

Rumination Reflection Questionnaire (RRQ)

Baseline
Ruminations between groups
Tidsramme: Month 4

Rumination Reflection Questionnaire (RRQ)

Month 4
Ruminations between groups
Tidsramme: Month 7

Rumination Reflection Questionnaire (RRQ)

Month 7
Number of self-destructive behaviors between groups
Tidsramme: Baseline

Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview

Baseline
Number of self-destructive behaviors between groups
Tidsramme: Month 4

Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview

Month 4
Number of self-destructive behaviors between groups
Tidsramme: Month 7

Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview

Month 7
Number of impulsive behaviors between groups
Tidsramme: Baseline

Number of impulsive behaviors (food, motor vehicles, sexual, drug-related)

Baseline
Number of impulsive behaviors between groups
Tidsramme: Month 4

Number of impulsive behaviors (food, motor vehicles, sexual, drug-related)

Month 4
Number of impulsive behaviors between groups
Tidsramme: Month 7

Number of impulsive behaviors (food, motor vehicles, sexual, drug-related)

Month 7
Level of suicide risk between groups
Tidsramme: Baseline

Columbia-Suicide Severity Rating Scale (C-SSRS)

Baseline
Level of suicide risk between groups
Tidsramme: Month 4

Columbia-Suicide Severity Rating Scale (C-SSRS)

Month 4
Level of suicide risk between groups
Tidsramme: Month 7

Columbia-Suicide Severity Rating Scale (C-SSRS)

Month 7
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Tidsramme: 12 Months prior to inclusion

Information taken from patient medical file

12 Months prior to inclusion
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Tidsramme: Baseline

Information taken from patient medical file

Baseline
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Tidsramme: Month 4

Information taken from patient medical file

Month 4
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Tidsramme: Month 7

Information taken from patient medical file

Month 7
Psychosocial functioning between groups
Tidsramme: Baseline

Functional Assessment Staging Tool (FAST)

Baseline
Psychosocial functioning between groups
Tidsramme: Month 4

Functional Assessment Staging Tool (FAST)

Month 4
Psychosocial functioning between groups
Tidsramme: Month 7

Functional Assessment Staging Tool (FAST)

Month 7
Implicit impulsivity between groups
Tidsramme: Baseline

Continuous Performance Test (CPT)

Baseline
Implicit impulsivity between groups
Tidsramme: Month 4

Continuous Performance Test (CPT)

Month 4
Implicit impulsivity between groups
Tidsramme: Month 7

Continuous Performance Test (CPT)

Month 7
Neurocognitive evaluation of implicit impulsivity between groups
Tidsramme: Baseline

Emotional Stroop (SE) customized to the study

Baseline
Neurocognitive evaluation of implicit impulsivity between groups
Tidsramme: Month 4

Emotional Stroop (SE) customized to the study

Month 4
Neurocognitive evaluation of implicit impulsivity between groups
Tidsramme: Month 7

Emotional Stroop (SE) customized to the study

Month 7
Risk taking between groups
Tidsramme: Baseline

Balloon Analogue Risk Task (BART)

Baseline
Risk taking between groups
Tidsramme: Month 4

Balloon Analogue Risk Task (BART)

Month 4
Risk taking between groups
Tidsramme: Month 7

Balloon Analogue Risk Task (BART)

Month 7
Decision making under risk conditions between groups
Tidsramme: Baseline

Game Dice Task (GDT)

Baseline
Decision making under risk conditions between groups
Tidsramme: Month 4

Game Dice Task (GDT)

Month 4
Decision making under risk conditions between groups
Tidsramme: Month 7

Game Dice Task (GDT)

Month 7

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Clémentine Estric, CHU de Nimes

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

8. november 2023

Primær fullføring (Faktiske)

13. september 2025

Studiet fullført (Faktiske)

22. desember 2025

Datoer for studieregistrering

Først innsendt

22. mai 2023

Først innsendt som oppfylte QC-kriteriene

12. juni 2023

Først lagt ut (Faktiske)

22. juni 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • NIMAO/2022-1/CE-01

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

All IPD that underlie results in a publication

IPD-delingstidsramme

Upon publication

Tilgangskriterier for IPD-deling

The IPD will be made available to other researchers upon reasonable request to the corresponding author

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • ICF
  • ANALYTIC_CODE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere